✦ LIBER ✦

RIVAROXABAN IN THE SETTING OF CONTINUED DUAL ANTIPLATELET THERAPY: FINDINGS FROM THE ATLAS ACS 2-TIMI 51 TRIAL

✍ Scribed by Mega, Jessica L.; Braunwald, Eugene; Murphy, Sabina; Plotnikov, Alexei; Cook-Bruns, Nancy; Aylward, Philip; Chopra, Vijay; Gao, Runlin; Nicolau, Jose; Gibson, C. Michael

Book ID: 122212094
Publisher: Elsevier Science
Year: 2013
Tongue: English
Weight: 223 KB
Volume: 61
Category: Article
ISSN: 1558-3597
DOI: 10.1016/S0735-1097(13)60005-4

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

RIVAROXABAN REDUCES SPONTANEOUS AND LARG

RIVAROXABAN REDUCES SPONTANEOUS AND LARGE MYOCARDIAL INFARCTIONS: FINDINGS FROM THE ATLAS ACS 2 – TIMI 51 TRIAL

✍ Cavender, Matthew; Braunwald, Eugene; Gibson, C. Michael; Wiviott, Stephen; Murp 📂 Article 📅 2013 🏛 Elsevier Science 🌐 English ⚖ 144 KB

The “Dual-Pathway” Strategy after Acute

The “Dual-Pathway” Strategy after Acute Coronary Syndrome: Rivaroxaban and Antiplatelet Agents in the ATLAS ACS 2-TIMI 51 Trial

✍ Cohen, Marc; Iyer, Deepa 📂 Article 📅 2014 🏛 Hindawi Limited 🌐 English ⚖ 630 KB

Rationale and design of the Anti-Xa Ther

Rationale and design of the Anti-Xa Therapy to Lower cardiovascular events in Addition to standard therapy in Subjects with Acute Coronary Syndrome–Thrombolysis in Myocardial Infarction 51 (ATLAS-ACS 2 TIMI 51) trial: A randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of rivaroxaban in subjects with acute coronary syndrome

✍ C. Michael Gibson; Jessica L. Mega; Paul Burton; Shinya Goto; Freek Verheugt; Ch 📂 Article 📅 2011 🏛 Elsevier Science 🌐 English ⚖ 428 KB